Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAISE: niraparib added to anti-PD-L1 maintenance for SLFN11-positive extensive-disease small cell lung cancer
2022-502092-33-00Phase 2Authorised
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- May 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, open-label trial of niraparib, durvalumab and atezolizumab in small cell lung cancer (SCLC) (2 arms), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Progression-free survival rate at 3 months. Planned start May 2024; status: authorised.
02
Drugs
niraparibdurvalumabatezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2022-502092-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502092-33-00.